Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hoenigl, M; Duettmann, W; Raggam, RB; Seeber, K; Troppan, K; Fruhwald, S; Prueller, F; Wagner, J; Valentin, T; Zollner-Schwetz, I; Wölfler, A; Krause, R.
Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.
Antimicrob Agents Chemother. 2013; 57(7):3262-3267
Doi: 10.1128/AAC.00251-13
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Hönigl Martin
- Krause Robert
- Co-Autor*innen der Med Uni Graz
- Düttmann Wiebke
- Fruhwald Sonja
- Prochazka Katharina
- Prüller Florian
- Rabensteiner Jasmin
- Raggam Reinhard Bernd
- Valentin Thomas
- Wölfler Albert
- Zollner-Schwetz Ines
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Voriconazole plasma concentrations (VPCs) vary widely, and concentrations outside the therapeutic range are associated with either worse outcome in invasive aspergillosis (IA) or increased toxicity. The primary goal of this cohort study conducted in a real-life setting was to identify potential factors associated with inadequate VPCs in ICU patients and patients with hematological malignancies. Within a period of 12 months, trough VPCs were obtained and analyzed with high-performance liquid chromatography, and the adequate range was defined as 1.5 to 5.5 mg/liter. VPCs of <1.5 mg/liter were defined as low, whereas VPCs of >5.5 mg/liter were defined as potentially toxic. A total of 221 trough VPCs were obtained in 61 patients receiving voriconazole, and 124/221 VPCs (56%) were found to be low. Multivariate analysis revealed that low VPCs were significantly associated with clinical failure of voriconazole, prophylactic use, younger age, underlying hematological malignancy, concomitant proton pump inhibitor (PPI) (pantoprazole was used in 88% of the patients), and absence of side effects. Low VPCs remained an independent predictor of clinical failure of voriconazole. The defined adequate range was reached in 79/221 (36%) VPCs. In 18 samples (8%), potentially toxic levels were measured. Multivariate analysis revealed higher body mass index (BMI), absence of hematological malignancy, therapeutic application, and diarrhea as factors associated with potentially toxic VPCs. Neurotoxic adverse events occurred in six patients and were mostly associated with VPCs in the upper quartile of our defined adequate range. In conclusion, potential factors like younger age, prophylaxis, underlying hematological malignancy, BMI, and concomitant PPI should be considered within the algorithm of voriconazole treatment.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Age Factors -
- Aged -
- Aged, 80 and over -
- Antifungal Agents - adverse effects
- Antifungal Agents - blood
- Antifungal Agents - therapeutic use
- Aspergillosis - blood
- Aspergillosis - drug therapy
- Body Mass Index -
- Cohort Studies -
- Drug Monitoring -
- Female -
- Hematologic Neoplasms - blood
- Hematologic Neoplasms - drug therapy
- Humans -
- Intensive Care Units -
- Male -
- Middle Aged -
- Prospective Studies -
- Pyrimidines - adverse effects
- Pyrimidines - blood
- Pyrimidines - therapeutic use
- Treatment Outcome -
- Triazoles - adverse effects
- Triazoles - blood
- Triazoles - therapeutic use
- Voriconazole -
- Young Adult -